×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Nextcure Inc. (NXTC) NASDAQ

$1.94 (0.04) (-1.78%)

Market Cap: $53.99M

As of 03/27/24 04:00 PM EDT. Market closed.

(NXTC)

Nextcure Inc. (NXTC)
NASDAQ

$1.94
(0.04) (-1.78%)

Market Cap: $53.99M

As of 03/27/24 04:00 PM EDT. Market closed.

Add to Portfolio

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel ... read more

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Michael Richman
Full Time Employees
101
CEO Compensation (Base)
$383,400
CEO Compensation (Total)
$2.50M
URL
Address
9000 Virginia Manor Rd Ste 200, Maryland, Beltsville, 20705-4214.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Michael Richman
Full Time Employees
101
CEO Compensation (Base)
$383,400
CEO Compensation (Total)
$2.50M
Address
9000 Virginia Manor Rd Ste 200, Maryland, Beltsville, 20705-4214.
PRICE CHART FOR NEXTCURE INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$1.97
Days Range
$1.74 - $1.95
52 week range
$0.98 - $2.09
Volume
520
Avg. Volume (30 days)
544,929
Market Cap
$53.99M
Dividend Yield
-
P/E
-
Shares Outstanding
27,903,027
Open
-
Previous Close
$1.97
Days Range
$1.74 - $1.95
52 week range
$0.98 - $2.09
Volume
520
Avg. Volume (30 days)
544,929
Market Cap
$53.99M
Dividend Yield
-
P/E
-
Shares Outstanding
27,903,027
FINANCIAL STATEMENTS FOR NEXTCURE INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR NEXTCURE INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Heller Kevin N.Chief Medical OfficerJul 14, 2020 Option Exercise$1.7727,22948,19549,011Jul 16, 2020, 04:51 PM
Liu LindaSVP, ResearchNov 27, 2019 Option Exercise$0.7555,23441,65655,234Feb 21, 2020, 04:11 PM
Sofinnova Venture Partners IX, L.P.10% OwnerNov 15, 2019 Buy$36.75150,0005,512,5002,671,856Nov 19, 2019, 09:47 PM
Sofinnova Venture Partners IX, L.P.10% OwnerMay 13, 2019 Buy$15.00400,0006,000,0002,521,856May 15, 2019, 05:59 PM
SHANNON TIMOTHY MDirectorMay 13, 2019 Buy$15.0050,000750,0002,254,442May 13, 2019, 07:33 PM
Khuong Chau QuangDirectorMay 13, 2019 Buy$15.00350,0005,250,0002,711,013May 13, 2019, 07:32 PM
Xu StellaDirectorMay 13, 2019 Buy$15.00125,0001,875,0001,103,570May 13, 2019, 07:32 PM
CANAAN X L.P.10% OwnerMay 13, 2019 Buy$15.0050,000750,0002,254,442May 13, 2019, 07:32 PM
ORBIMED ADVISORS LLCDirectorMay 13, 2019 Buy$15.00350,0005,250,0002,711,013May 13, 2019, 07:32 PM
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Heller Kevin N.Chief Medical Officer07/14/202048,195
Liu LindaSVP, Research11/27/201941,656
Sofinnova Venture Partners IX, L.P.10% Owner11/15/20195,512,500
Sofinnova Venture Partners IX, L.P.10% Owner05/13/20196,000,000
SHANNON TIMOTHY MDirector05/13/2019750,000
Khuong Chau QuangDirector05/13/20195,250,000
Xu StellaDirector05/13/20191,875,000
CANAAN X L.P.10% Owner05/13/2019750,000
ORBIMED ADVISORS LLCDirector05/13/20195,250,000
FUNDS WITH A POSITION IN NEXTCURE INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ORBIMED ADVISORS LLC1,268,0130.04%-53.23%Other
BLACKROCK INC.890,1020.00003%-0.89%Other
RENAISSANCE TECHNOLOGIES LLC293,3150.00052%17.23%Other
GEODE CAPITAL MANAGEMENT, LLC174,7070.00002%No changeOther
CHANGE IN SHARES OUTSTANDING FOR NEXTCURE INC
STOCK BUYBACKS FOR NEXTCURE INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
0.22%
1Q
12/31/2023
06/30/2023
0.26%
2Q
12/31/2023
03/31/2023
0.46%
3Q
12/31/2023
12/31/2022
0.46%
4Q
12/31/2023
09/30/2022
0.55%
5Q
12/31/2023
06/30/2022
0.57%
6Q
12/31/2023
03/31/2022
0.70%
7Q
12/31/2023
12/31/2021
0.95%
8Q
12/31/2023
09/30/2021
1.04%
9Q
12/31/2023
06/30/2021
1.06%
10Q
12/31/2023
03/31/2021
1.10%
11Q
12/31/2023
12/31/2020
1.26%
12Q
12/31/2023
09/30/2020
1.29%
13Q
12/31/2023
06/30/2020
1.40%
14Q
12/31/2023
03/31/2020
-4.93%
15Q
12/31/2023
12/31/2019
77.77%
16Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
0.22%
1Q
06/30/2023
0.26%
2Q
03/31/2023
0.46%
3Q
12/31/2022
0.46%
4Q
09/30/2022
0.55%
5Q
06/30/2022
0.57%
6Q
03/31/2022
0.70%
7Q
12/31/2021
0.95%
8Q
09/30/2021
1.04%
9Q
06/30/2021
1.06%
10Q
03/31/2021
1.10%
11Q
12/31/2020
1.26%
12Q
09/30/2020
1.29%
13Q
06/30/2020
1.40%
14Q
03/31/2020
-4.93%
15Q
12/31/2019
77.77%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR NEXTCURE INC
LOADING...